Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the ...
At Pfizer, interviews are a significant component of our hiring assessment process. The purpose of an interview is to get to know you better as a person, give you an opportunity to share your amazing ...
The HER2CLIMB-05 trial is a randomized, double blind, placebo-controlled, pivotal Phase 3 study evaluating the efficacy and safety of TUKYSA compared to placebo, both in combination with trastuzumab ...
NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company’s common stock, payable December 7, 2026, ...
LITFULO significantly improved facial and total body repigmentation at Week 52 compared to placebo, with continuous improvement starting at Week 24, supporting planned regulatory filings for a ...
As we enter fall, the days are getting shorter and the nights are getting cooler, but Pfizer’s social media channels are as active as ever. In September, we highlighted Blood and Prostate Cancer ...
(NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-t ...
Data across 45 abstracts will highlight new evidence for established medicines, including PADCEV and TALZENNA, and promising late-stage pipeline candidates such as atirmociclib and tivunatamig ...
Long before reaching pharmacy shelves, every new medicine must complete one or more clinical trials. But before researchers can determine whether a potential new treatment is effective, they have to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results